UL samples harbored secondary mutations in established tumor suppressors (CDKN2C: p.L21H, PTEN: p.S229L) and the transcriptional coactivator CREBBP (p.C2725T), none of which appeared in FA samples (Figure 1B). This evidence concerns the gene CDKN2C and Friedreich ataxia.